MEDANTA

Global Health Limited's Nomination & Remuneration Committee on May 23, 2026, approved the allotment of 15,900 Equity Shares of face value Rs. 2/- each at a premium of Rs. 1,239 per share to the GHL Employees Welfare Trust under the GHL LTIP 2024 Plan. This action increases the company's paid-up share capital from Rs. 53,77,03,764/- to Rs. 53,77,35,564/-. The shares will be transferred to eligible employees' Demat Accounts.

Global Health Limited (MEDANTA) announced it will meet with institutional investors/analysts. Management will hold one-on-one meetings with ICICI Prudential AMC Ltd on May 27, 2026, in Gurugram, and IIFL Capital Asset Management Limited on May 28, 2026, virtually. No Unpublished Price Sensitive Information will be shared during these meetings.

Global Health Limited (MEDANTA) has scheduled one-on-one meetings with institutional investors. The company's management will meet ICICI Prudential AMC Ltd on May 27, 2026, in Gurugram, and IIFL Capital Asset Management Limited on May 28, 2026, virtually. The company explicitly stated that no Unpublished Price Sensitive Information (UPSI) will be shared during these interactions.

The management discussed a strong FY26 performance and positive outlook. The Noida hospital is expected to break even in H2 FY27. The company plans to add approximately 500 beds in existing hospitals in the short term and about 2,700 beds through 5 greenfield projects over the next 3-4 years. Total project capex for the next 5 years is estimated at INR 45,000 Cr, with FY27 capex projected at INR 800-900 Cr and FY28 at INR 600-700 Cr. Growth will be driven by adding new services, procedures, specialties, expanding existing facilities, and new units like the 80-bed Indore hospital (Q2 FY27). Mature unit margins are expected to remain stable at 24-25%. The company maintains a strong net cash position of INR 5,906 Cr as of March 31, 2026.

Global Health Limited (Medanta) announced the availability of the audio recording of its Earnings Conference Call held on May 15, 2026. The call discussed the financial results for the Fourth Quarter and Financial Year ended March 31, 2026. The recording can be accessed through the link provided on the company's investor relations website.

Consolidated Revenue from operations for Q4 FY26 was INR 1,159 Cr vs INR 931.3 Cr (▲24.5% YoY), EBITDA was INR 290.6 Cr vs INR 247.8 Cr (▲17.3% YoY), and PAT was INR 141.7 Cr vs INR 101.4 Cr (▲39.7% YoY). EBITDA Margin was 24.3% vs 26.0% (▼170bps). The company reported its highest ever quarterly total income and strong operational performance, including an increase in bed capacity and patient volumes.

The Board of Directors of Global Health Limited met on May 14, 2026, approving the Audited Standalone and Consolidated Financial Results for Q4 and the financial year ended March 31, 2026. A final dividend of Rs. 0.50/- per equity share was recommended. The Board also approved the appointment of Mr. Kedar Ashok Apte as Chief Marketing & Growth Officer and Mr. Jagdeep Singh as General Counsel (both Senior Management Personnel). Ms. Richa Singh, an existing Senior Management Personnel, resigned, effective May 20, 2026.

Global Health Limited's Board of Directors approved the Audited Standalone and Consolidated Financial Results for Q4 and FY ended March 31, 2026. A final dividend of Rs. 0.50/- per equity share (25% on Rs. 2/- face value) was recommended for FY26. The board also appointed Mr. Kedar Ashok Apte as Chief Marketing & Growth Officer and Mr. Jagdeep Singh as General Counsel. Ms. Richa Singh, a Senior Management Personnel, resigned effective May 20, 2026.

New Filing detected. See link for details.

Global Health Limited (Medanta) announced an earnings conference call for its Q4 FY2026 financial results. The call is scheduled for Friday, May 15, 2026, at 2:00 PM IST, hosted by ICICI Securities. Key management, including the Chairman & MD, Group CEO, and CFO, will represent the company.

Global Health Limited's Nomination & Remuneration Committee approved the grant of 10,000 Employee Stock Options (ESOPs) to one employee under the GHL LTIP 2024 Plan on May 11, 2026. The exercise price per option is ₹960. These options will vest over a maximum of 5 years and can be exercised within 3 years from the vesting of the last installment.